JLJohn T. Lear

John T. Lear

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John T. Lear has a total of 389 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma

    by John T. Lear, Reinhard Dummer, Alexander Guminski

    Https://doi.org/10.18632/oncotarget.28145 John T. Lear, Reinhard Dummer, Alexander Guminski


  • Open Access

    Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial

    by John T Lear, Axel Hauschild, Eggert Stockfleth, Nicholas Squittieri, Nicole Basset-Seguin, Reinhard Dummer

    Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial


  • Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome.

    by Ervin H Epstein, John Lear, Gillian Saldanha, Jean Y. Tang, Catherine Harwood

    E21626Background: Oral hedgehog (HH) inhibitors can produce complete clinical and histologic remission of non-advanced basal cell carcinomas (BCCs) in patients with Gorlin syndrome. However, class-specific hair loss, taste loss, and muscle cramps cause most patients to discontinue treatment, following which BCCs recur. PellePharm’s goal is to develop a topical HH inhibitor with sufficient percutaneous absorption to have anti-HH/BCC-preventive activity, but without enough absorption to produce the characteristic systemic AEs. This would be a first in class topical drug to manage the chronic burden of continuously developing BCC tumors in Gorlin patients. We report here the first Phase 2 double-blind, vehicle controlled randomized trial of topical patidegib, a small molecule HH inhibitor derived from plant-produced cyclopamine. Methods: In this Phase 2 clinical trial, patients with Gorlin syndrome applied vehicle (n = 5), 2% patidegib (n = 6), or 4% patidegib (n = 6) gel twice daily for six months to their ...


  • Top Cited Papers
    Open Access

    Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

    by J.T. Lear, M.R. Migden, K.D. Lewis, A.L.S. Chang, A. Guminski, R. Gutzmer, L. Dirix, P. Combemale, A. Stratigos, R. Plummer, et al.

    Background: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial.Objective: To evaluate long‐term efficacy and safety of sonidegib in laBCC and mBCC in the BOLT 18‐ and 30‐month analyses.Methods: BOLT (NCT01327053, ClinicalTrials.gov), a double‐blind phase 2 study, enrolled patients from July 2011 until January 2013. Eligible HPI‐treatment–naïve patients with laBCC not amenable to curative surgery/radiotherapy or mBCC were randomized 1 : 2 to sonidegib 200 mg (laBCC, n = 66; mBCC, n = 13) or 800 mg (laBCC, n = 128; mBCC, n = 23). Tumour response was assessed per central and investigator review.Results: With 30 months of follow‐up, among patients treated with sonidegib 200 mg (approved dose), objective response rates were 56.1% (central) and 71.2% (investigator) in laBCC and 7.7% (central) and 23.1% (investigator) in mBCC. Tumour responses were durable as follows: median duration of response was 26.1 months (central) and 15.7 months (investigator) in laBCC and 24.0 months (central) and 18.1 months (investigator) in mBCC. Five patients with laBCC and three with mBCC in the 200‐mg arm died. Median overall survival was not reached in either population; 2‐year overall survival rates were 93.2% (laBCC) and 69.3% (mBCC). In laBCC, efficacy was similar regardless of aggressive or non‐aggressive histology. Sonidegib 200 mg continued to have a better safety profile than 800 mg, with lower rates of grade 3/4 adverse events (43.0% vs. 64.0%) and adverse events leading to discontinuation (30.4% vs. 40.0%).Conclusion: Sonidegib continued to demonstrate long‐term efficacy and safety in these populations. These data support the use of sonidegib 200 mg per local treatment guidelines.


  • Open Access

    Photodynamic Therapy and Non-Melanoma Skin Cancer

    by Liezel L. Griffin, John T. Lear

    Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management.


  • Benign Keratinocytic Acanthomas and Proliferations

    by Vishal Madan, John T. Lear

    Benign keratinocytic acanthomas and proliferations are commonly presenting dermatoses with varied but distinct clinical and histological presentations. Whilst many such as seborrhoeic keratoses are easily diagnosed clinically, histology is mandatory in pseudoepitheliomatous hyperplasia as clinical distinction from squamous cell carcinoma can be very difficult.


  • The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.

    by Nicholas J. Collier, Faisal R. Ali, John T. Lear

    Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated laBCCs represent 1% of BCCs. Sonidegib is an oral hedgehog pathway inhibitor with a novel structure. It has recently been licensed for the treatment of laBCC. This article provides a comprehensive review of the literature regarding sonidegib, detailing the pharmacology of the compound, clinical trial data, competitor compounds and a future perspective. Expert commentary: Sonidegib is a novel smoothened (SMO) inhibitor with comparable efficacy to vismodegib, with patient response rates of 44% (sonidegib) and 43% (vismodegib). The adverse effect profile of these two treatments is similar with the main effects being considered to be class effects of SMO inhibitors.


  • Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.

    by Reinhard Dummer, Michael Robert Migden, Alexander Guminski, Ralf Gutzmer, Ragini Reiney Kudchadkar, Karl D. Lewis, Luc Dirix, Patrick Combemale, Uwe Trefzer, Carmen Loquai, et al.

    9538 Background: Sonidegib 200 mg was approved for use in pts with advanced BCC (aBCC; laBCC + mBCC) or laBCC not amenable to surgery/radiotherapy based on results from BOLT (NCT01327053). Updated data from the 30-month analysis (July 10, 2015 cutoff; 38.2-mo median follow-up) are reported. Methods: Pts with laBCC or mBCC received sonidegib 200 or 800 mg daily. Objective response rate (ORR; complete response [CR] + partial response [PR]), duration of response (DOR), and progression-free survival (PFS) were assessed in laBCC (all pts; pts with aggressive [eg, micronodular, infiltrative] and nonaggressive [nodular/superficial] subtypes) per modified RECIST and in mBCC per RECIST v1.1 by central review. Results: Median duration of exposure was 11.0 mo (200 mg) and 6.6 mo (800 mg). In laBCC, ORRs were 56% (200 mg) and 45% (800 mg; Table) and were similar in pts with aggressive vs nonaggressive BCCs (200 mg, 59% [n = 37] vs 52% [n = 29]; 800 mg, 44% [n = 75] vs 47% [n = 53]). Median DOR was > 23 mo; median PFS was ≈ 22 mo. In mBCC, ORRs were 8% (200 mg) and 17% (800 mg); disease control rates (DCRs; CR + PR + stable disease) were 92% (200 mg) and 91% (800 mg). Sonidegib 200 mg continued to have a more favorable safety profile than 800 mg, with fewer grade 3/4 adverse events (AEs; 43% vs 64%) and discontinuations due to AEs (30% vs 40%). The most common AEs (any grade) were muscle spasms (200/800 mg, 54%/69%), alopecia (49%/58%), and dysgeusia (44%/60%). Conclusions: Durable responses and long-term safety were demonstrated with sonidegib in the BOLT 30-month analysis. These data support the use of sonidegib for the treatment of pts with aBCC per local guidelines. Clinical trial information: NCT01327053.


  • Open Access

    Non-melanoma skin cancer

    by Liezel L Griffin, Faisal Rehman Ali, John T Lear

    Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the ‘gold-standard’ treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.